Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Hypoxia Selectively Impairs CAR-T Cells In Vitro.

Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L.

Cancers (Basel). 2019 Apr 30;11(5). pii: E602. doi: 10.3390/cancers11050602.

2.

Generation of CAR-T Cells for Cancer Immunotherapy.

Xu Q, Harto H, Berahovich R, Xu S, Zhou H, Golubovskaya V, Wu L.

Methods Mol Biol. 2019;1884:349-360. doi: 10.1007/978-1-4939-8885-3_24.

PMID:
30465215
3.

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.

Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V.

Cancers (Basel). 2018 Sep 11;10(9). pii: E323. doi: 10.3390/cancers10090323.

4.

GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

Golubovskaya VM, Berahovich R, Xu Q, Zhou H, Xu S, Guan J, Harto H, Li L, Wu L.

Front Biosci (Landmark Ed). 2018 Jun 1;23:2245-2254.

PMID:
29772559
5.

CAR-T Cell Therapy: From the Bench to the Bedside.

Golubovskaya V.

Cancers (Basel). 2017 Oct 31;9(11). pii: E150. doi: 10.3390/cancers9110150.

6.

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L, Chao CC, Mao MM, Wu L.

Cancers (Basel). 2017 Oct 21;9(10). pii: E139. doi: 10.3390/cancers9100139.

7.

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.

Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, Liu F, Golubovskaya VM, Wu L.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1644-1654.

PMID:
28410137
8.

Major Highlights of the CAR-TCR Summit, Boston, 2016.

Golubovskaya V, Berahovich R, Xu S, Harto H, Wu L.

Anticancer Agents Med Chem. 2017;17(10):1344-1350. doi: 10.2174/1871520617666170110151900.

PMID:
28071584
9.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.

10.

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

Golubovskaya V, Wu L.

Cancers (Basel). 2016 Mar 15;8(3). pii: E36. doi: 10.3390/cancers8030036. Review.

11.

Synthesis and bioactivity of a Goralatide analog with antileukemic activity.

Li Z, Lebedyeva IO, Golubovskaya VM, Cance WG, Alamry KA, Faidallah HM, Dennis Hall C, Katritzky AR.

Bioorg Med Chem. 2015 Aug 1;23(15):5056-60. doi: 10.1016/j.bmc.2015.04.061. Epub 2015 May 14.

PMID:
26048023
12.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3. Epub 2015 Feb 6.

PMID:
25656374
13.

Defective apical extrusion signaling contributes to aggressive tumor hallmarks.

Gu Y, Shea J, Slattum G, Firpo MA, Alexander M, Mulvihill SJ, Golubovskaya VM, Rosenblatt J.

Elife. 2015 Jan 26;4:e04069. doi: 10.7554/eLife.04069.

14.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

15.
16.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

17.

In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).

Golubovskaya V, Curtin L, Groman A, Sexton S, Cance WG.

Arch Toxicol. 2015 Jul;89(7):1095-101. doi: 10.1007/s00204-014-1290-y. Epub 2014 Jun 12.

PMID:
24915938
18.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

19.

Focal adhesion kinase and cross-linked signaling in cancer.

Golubovskaya VM.

Anticancer Agents Med Chem. 2014 Jan;14(1):2. No abstract available.

PMID:
24410522
20.

Targeting FAK in human cancer: from finding to first clinical trials.

Golubovskaya VM.

Front Biosci (Landmark Ed). 2014 Jan 1;19:687-706. Review.

21.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

22.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

23.

Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.

Heffler M, Golubovskaya VM, Dunn KM, Cance W.

Cancer Biol Ther. 2013 Aug;14(8):761-72. doi: 10.4161/cbt.25185. Epub 2013 Jun 3.

24.

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Cance WG, Kurenova E, Marlowe T, Golubovskaya V.

Sci Signal. 2013 Mar 26;6(268):pe10. doi: 10.1126/scisignal.2004021. Review.

25.

MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.

Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG.

Anticancer Agents Med Chem. 2014 Jan;14(1):18-28.

26.
27.

Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells.

Ho B, Huang G, Golubovskaya VM.

Anticancer Agents Med Chem. 2014 Jan;14(1):3-8.

28.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

29.

Survival signaling through focal adhesion kinase in tumors.

Golubovskaya VM.

Anticancer Agents Med Chem. 2013 May;13(4):531. No abstract available.

PMID:
22934710
30.

FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Heffler M, Golubovskaya VM, Conroy J, Liu S, Wang D, Cance WG, Dunn KB.

Anticancer Agents Med Chem. 2013 May;13(4):584-94.

31.

FAK and Nanog cross talk with p53 in cancer stem cells.

Golubovskaya VM.

Anticancer Agents Med Chem. 2013 May;13(4):576-80. Review.

32.

Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM.

J Biol Chem. 2012 May 25;287(22):18656-73. doi: 10.1074/jbc.M111.322883. Epub 2012 Apr 5.

33.

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG.

Carcinogenesis. 2012 May;33(5):1004-13. doi: 10.1093/carcin/bgs120. Epub 2012 Mar 7.

34.

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):546-54.

35.

A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.

Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):532-45.

36.

Editorial: Focal adhesion kinase signaling in cancer--Part II.

Golubovskaya VM.

Anticancer Agents Med Chem. 2011 Sep;11(7):591-2. No abstract available.

PMID:
21787274
37.

Focal adhesion kinase protein regulates Wnt3a gene expression to control cell fate specification in the developing neural plate.

Fonar Y, Gutkovich YE, Root H, Malyarova A, Aamar E, Golubovskaya VM, Elias S, Elkouby YM, Frank D.

Mol Biol Cell. 2011 Jul 1;22(13):2409-21. doi: 10.1091/mbc.E10-12-0932. Epub 2011 May 5.

38.

Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis.

Teng BP, Heffler MD, Lai EC, Zhao YL, LeVea CM, Golubovskaya VM, Bullarddunn KM.

Anticancer Agents Med Chem. 2011 Sep;11(7):620-8.

39.

FAK and p53 protein interactions.

Golubovskaya VM, Cance WG.

Anticancer Agents Med Chem. 2011 Sep;11(7):617-9. Review.

40.

Targeting focal adhesion kinase in cancer-part I.

Golubovskaya VM.

Anticancer Agents Med Chem. 2010 Dec;10(10):713. No abstract available.

PMID:
21348852
41.

Evolving therapies and FAK inhibitors for the treatment of cancer.

Dunn KB, Heffler M, Golubovskaya VM.

Anticancer Agents Med Chem. 2010 Dec;10(10):722-34. Review.

42.

Focal adhesion kinase as a cancer therapy target.

Golubovskaya VM.

Anticancer Agents Med Chem. 2010 Dec;10(10):735-41. Review.

43.

Focal adhesion kinase and p53 signal transduction pathways in cancer.

Golubovskaya VM, Cance W.

Front Biosci (Landmark Ed). 2010 Jun 1;15:901-12. Review.

44.

Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM.

Cell Cycle. 2010 Mar 1;9(5):1005-15. Epub 2010 Mar 14.

45.

Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.

Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY.

Life Sci. 2010 Jan 30;86(5-6):199-206. doi: 10.1016/j.lfs.2009.12.003. Epub 2009 Dec 22.

PMID:
20006625
46.

Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.

Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, Golubovskaya VM.

Mol Carcinog. 2010 Mar;49(3):224-34. doi: 10.1002/mc.20592.

47.

A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.

Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN.

Mol Carcinog. 2010 Feb;49(2):200-9. doi: 10.1002/mc.20590.

48.
49.

Targeting of the protein interaction site between FAK and IGF-1R.

Zheng D, Kurenova E, Ucar D, Golubovskaya V, Magis A, Ostrov D, Cance WG, Hochwald SN.

Biochem Biophys Res Commun. 2009 Oct 16;388(2):301-5. doi: 10.1016/j.bbrc.2009.07.156. Epub 2009 Aug 5.

50.

A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.

Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM.

Cell Cycle. 2009 Aug;8(15):2435-43. Epub 2009 Aug 1.

Supplemental Content

Loading ...
Support Center